Pharmacokinetics and renal disposition of polymyxin B in an animal model

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5724-5727

  Abdelraouf, Kamilia ^a   He, Jie ^a   Ledesma, Kimberly R ^a   Hu, Ming ^a   Tam, Vincent H ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYMYXIN DERIVATIVE;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; FEMALE; KIDNEY CELL; KIDNEY FAILURE; KIDNEY PARENCHYMA; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINALYSIS; URINARY EXCRETION;

ACUTE KIDNEY INJURY; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL TRANSPORT; CHROMATOGRAPHY, LIQUID; FEMALE; INJECTIONS, INTRAVENOUS; KIDNEY; METABOLIC CLEARANCE RATE; POLYMYXIN B; RATS; RATS, SPRAGUE-DAWLEY; TANDEM MASS SPECTROMETRY; URANYL NITRATE;

EID: 84868028805     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01333-12     Document Type: Article

References (19)

1. Abdelraouf K, et al. 2012. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob. Agents Chemother. 56:4625-4629.
2. D'Argenio DZ, Schumitzky A. 1997. ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
3. Elias LS, Konzen D, Krebs JM, Zavascki AP. 2010. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J. Antimicrob. Chemother. 65:2231-2237.
4. Giacomini KM, Roberts SM, Levy G. 1981. Evaluation of methods for producing renal dysfunction in rats. J. Pharm. Sci. 70:117-121.
5. He J, et al. 2010. Variability of polymyxin B major components in commercial formulations. Int. J. Antimicrob. Agents 35:308-310.
6. Hoeprich PD. 1970. The polymyxins. Med. Clin. North Am. 54:1257-1265.
7. Ko KS, et al. 2007. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J. Antimicrob. Chemother. 60:1163-1167.
8. Kunin CM. 1970. Binding of antibiotics to tissue homogenates. J. Infect. Dis. 121:55-64.
9. Kunin CM, Bugg A. 1971. Binding of polymyxin antibiotics to tissues: the major determinant of distribution and persistence in the body. J. Infect. Dis. 124:394-400.
10. Kwa AL, Abdelraouf K, Low JG, Tam VH. 2011. Pharmacokinetics of polymyxin B in a patient with renal insufficiency: a case report. Clin. Infect. Dis. 52:1280-1281.
11. Kwa AL, et al. 2008. Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. Diagn. Microbiol. Infect. Dis. 60:163-167.
12. Kwa AL, Tam VH, Falagas ME. 2008. Polymyxins: a review of the current status including recent developments. Ann. Acad. Med. Singapore 37: 870-883.
13. Landman D, Bratu S, Alam M, Quale J. 2005. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibilityto polymyxin B. J. Antimicrob. Chemother. 55:954-957.
14. Orwa JA, et al. 2001. Isolation and structural characterization of polymyxin B components. J. Chromatogr. A 912:369-373.
15. Ouderkirk JP, Nord JA, Turett GS, Kislak JW. 2003. Polymyxin B nephrotoxicity and efficacy against nosocomial infections caused by multiresistant gram-negative bacteria. Antimicrob. Agents Chemother. 47: 2659-2662.
16. Satlin MJ, et al. 2011. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob. Agents Chemother. 55:5893-5899.
17. Tam VH, Cao H, Ledesma KR, Hu M. 2011. In vitro potency of various polymyxin B components. Antimicrob. Agents Chemother. 55:4490-4491.
18. Yuan Z, Tam VH. 2008. Polymyxin B: a new strategy for multidrugresistant Gram-negative organisms. Expert Opin. Investig. Drugs 17:661-668.
19. Zavascki AP, et al. 2008. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin. Infect. Dis. 47:1298-1304.